Luye Pharma Launches Erzofri in the US for Schizophrenia and Schizoaffective Disorder
Shots:
- Luye Pharma has launched Erzofri extended-release injectable suspension in the US to treat adults with schizophrenia & as monotx. or adjunct therapy for adults with schizoaffective disorder
- Erzofri was approved by the US FDA based on a multiple-dose, parallel-group study evaluating its PK profile & relative bioavailability at steady state vs reference product, demonstrating bioequivalence to established paliperidone palmitate LAI on day 8 without requiring the 2nd initiation dose
- Erzofri simplifies treatment with a unique 351mg/2.25mL single-dose initiation & is available in single-use kits across multiple strengths: 39mg/0.25mL, 78mg/0.5mL, 117mg/0.75mL, 156mg/1mL, & 234mg/1.5mL
Ref: Prnewswire | Image: Luye Pharma
Related News:- ABL Bio Licenses Grabody-B Brain Delivery Platform to GSK for ~$2.76B (£2.15B)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
